Table 6.
Metastasis-free survival analysis (N = 20).
| Factor | Patients | Events (metastasis) | Median (months) | P-value (log rank test) |
|---|---|---|---|---|
| Age at diagnosis (years) | ||||
| ≤ 15 | 6 | 4 | 11.1 | 0.984 |
| > 15 | 14 | 9 | 9.7 | |
| Gender | ||||
| Male | 11 | 10 | 8.9 | 0.027 |
| Female | 9 | 3 | Undefined | |
| Enneking stage | ||||
| IIB | 18 | 11 | 10.8 | < 0.001 |
| III | 2 | 2 | 1.2 | |
| Site | ||||
| Extremities | 16 | 11 | 9.5 | 0.478 |
| Axial | 4 | 2 | 24.2 | |
| IMPDH2 expression | ||||
| Low (IRS ≤ 6) | 6 | 2 | Undefined | 0.030 |
| High (IRS > 6) | 14 | 11 | 6.9 | |
| HPRT expression | ||||
| Low (IRS ≤ 6) | 9 | 5 | 11.5 | 0.640 |
| High (IRS > 6) | 11 | 8 | 9.3 | |
| IMPDH2/HPRT ratio | ||||
| Low IMPDH2/HPRT | 16 | 11 | 9.1 | 0.472 |
| High IMPDH2/HPRT | 4 | 2 | 53.4 | |
P values were calculated using the log-rank test. P values < 0.05 shown in bold.